The Role of Early Biologic Therapy in Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2019 Apr 01;:
Authors: Berg DR, Colombel JF, Ungaro R
The goals for treatment of inflammatory bowel diseases (IBDs) are changing from elimination of symptoms toward complete disease control-a process that demands both clinical and endoscopic remission. This new IBD treatment paradigm has been shifting from a conventional “step-up” approach toward a more “top-down” early intervention treatment strategy. Recent studies suggest that the use of biologic agents, specifically those targeting tumor necrosis factor alpha, earlier in the treatment course improves patient outcomes and can prevent progression to irreversible bowel damage. Although the strategy of early intervention has accumulating evidence in Crohn’s disease, there is less evidence supporting its impact in ulcerative colitis.
PMID: 30934053 [PubMed – as supplied by publisher]